Overview

Novel Clinical Target in Fragile X Syndrome

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder (ASD). The investigators wish to examine brain distribution of sigma-1 receptors in young adult males with FXS using 18F-FTC-146 PET. This project will study the distribution of sigma-1 receptors in 15 young (18-30 years) male adults with FXS compared to 5 healthy adult volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Guido A. Davidzon, MD, MS
Stanford University